OTCM
VACBF
Market cap132mUSD
Oct 26, Last price
1.58USD
Name
Nykode Therapeutics ASA
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
2.22%
Rev. 5Y
151.20%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
-100.00%
Net income
-13m
L-67.54%
CFO
-27m
L-47.94%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
Key people
Barbara Krebs-pohl
Chairman of the Board · since 2026
Chief Executive Officer · since 2017
Harald Gurvin
Chief Financial Officer · since 2021
Elise Ramse
Chief Human Resources Officer · since 2021
Mette Husbyn
Chief Technical Officer · since 2017
Mikkel Pedersen
Chief Scientific Officer · since 2021
Klaus Edvardsen
Chief Development Officer · since 2022
Peter Fatum
Director, Head of QA · since 2021
Chief Innovation and Strategy Officer · since 2021
Katrine Husum
Senior Director, Head of Project and Alliance Management · since 2020
Siri Torhaug
Chief Medical Officer · since 2020
Christian Abyholm
Director · since 2020
John Beadle
Director · since 2026
Trygve Lauvdal
Director · since 2025
Susanne Stuffers
Chairman of the Board · since 2025
Headquarters & legal address
Gaustadalleen 21
Oslo 0349
NO
Oslo 0349
NO
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||